Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | TPMT | P51580 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | NNMT | P40261 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10953308 | 0.87 | TPMT (0.46) | GAAALDH1A1KDM4EHPGDTPMT | |
| SCHEMBL24453254 | 0.85 | KDM4E (0.55) | GAAALDH1A1KDM4EHPGDHTT | |
| SCHEMBL10862772 | 0.83 | ACHE (0.43) | GAAALDH1A1KDM4EACHEHTR4 | |
| SCHEMBL7165339 | 0.80 | TSHR (0.53) | ALDH1A1KDM4EHPGDTPMTHTT | |
| SCHEMBL14776122 | 0.77 | ALDH1A1 (0.46) | GAAALDH1A1KDM4EACHEHTR4 | |
| SCHEMBL6772316 | 0.77 | HSD17B10 (0.44) | GAAALDH1A1KDM4EHPGDTPMT | |
| SCHEMBL6782175 | 0.75 | GAA (0.54) | GAAALDH1A1KDM4EHPGDHTT | |
| SCHEMBL29238015 | 0.74 | ALDH1A1 (0.38) | GAAALDH1A1KDM4EHPGDTPMT | |
| SCHEMBL9929474 | 0.73 | GAA (0.41) | GAAALDH1A1KDM4EHPGDTPMT | |
| SCHEMBL11468821 | 0.73 | HSD17B10 (0.47) | GAAALDH1A1KDM4EHPGDTPMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820717-B2 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20090054495-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054495-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | GAA 3049/4885ALDH1A1 2607/4885KDM4E 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.